Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) EBITDA (2016 - 2025)

Historic EBITDA for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$25.1 million.

  • Capricor Therapeutics' EBITDA fell 9907.34% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.3 million, marking a year-over-year decrease of 10533.12%. This contributed to the annual value of -$39.7 million for FY2024, which is 7882.88% down from last year.
  • According to the latest figures from Q3 2025, Capricor Therapeutics' EBITDA is -$25.1 million, which was down 9907.34% from -$26.3 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' EBITDA peaked at -$682511.0 during Q4 2023, and registered a low of -$26.3 million during Q2 2025.
  • Moreover, its 5-year median value for EBITDA was -$6.9 million (2023), whereas its average is -$9.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 9115.26% in 2023, then crashed by 80841.03% in 2024.
  • Over the past 5 years, Capricor Therapeutics' EBITDA (Quarter) stood at -$6.2 million in 2021, then dropped by 24.61% to -$7.7 million in 2022, then skyrocketed by 91.15% to -$682511.0 in 2023, then crashed by 808.41% to -$6.2 million in 2024, then tumbled by 305.07% to -$25.1 million in 2025.
  • Its EBITDA stands at -$25.1 million for Q3 2025, versus -$26.3 million for Q2 2025 and -$6.2 million for Q4 2024.